Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06577090 · ClinicalTrials.gov registry record · Phase 2

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

A Phase 2 study of Obesity, sponsored by Skye Bioscience.

Active
Registry status
Phase 2
Development phase
136
Enrollment target
16
Study locations

NCT06577090: Active Phase 2 study of Obesity, sponsored by Skye Bioscience.

NCT06577090 is a Phase 2 study of Obesity that is active but no longer recruiting, run by Skye Bioscience. The registered enrollment target is 136 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The trial reports 16 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06577090, a Phase 2 study of Obesity, is active but no longer recruiting, sponsored by Skye Bioscience.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
136 participants
Enrollment target
16
Study locations

Study Summary

This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.

Conditions Studied

Obesity

Interventions

  • BIOLOGICAL Nimacimab injection
  • BIOLOGICAL Nimacimab placebo injection
  • COMBINATION_PRODUCT semaglutide injection
  • BIOLOGICAL Nimacimab 300 mg injection

Study Locations (16)

Georgia

  • ACCEL Research Sites - Atlanta
  • Center for Advanced Research & Education - Gainesville

Texas

  • Velocity Clinical Research, Dallas - Dallas
  • Be Well Clinical Studies - Round Rock

Alabama

  • Pinnacle Research Group - Anniston

California

  • Diablo Clinical Research, Inc. - Walnut Creek

Connecticut

  • Chase Medical Research, LLC - Waterbury

Kentucky

  • L-MARC Research Center - Louisville

Nebraska

  • Be Well Clinical Studies - Lincoln

Nevada

  • Palm Research Center - Las Vegas

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2024-08-22
Est. Completion 2027-02-28
Phase Phase 2

Sponsor

Skye Bioscience

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06577090

The ClinicalTrials.gov registry entry for NCT06577090 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (83% lower). The listed sponsor is Skye Bioscience, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 4 interventions - of which Nimacimab injection is the first listed.

NCT06577090 reports 16 study locations spanning 14 distinct geographic areas - top geographies include Georgia, Texas, Alabama.

Frequently Asked Questions

What is clinical trial NCT06577090 about?

NCT06577090 is a clinical study titled "Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo". This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.

What is the current status of trial NCT06577090?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2024-08-22. Estimated completion is 2027-02-28.

What conditions does trial NCT06577090 study?

This clinical trial studies the following conditions: Obesity.

What interventions are being tested in trial NCT06577090?

The interventions under investigation include: Nimacimab injection (BIOLOGICAL), Nimacimab placebo injection (BIOLOGICAL), semaglutide injection (COMBINATION_PRODUCT), Nimacimab 300 mg injection (BIOLOGICAL).

Who is sponsoring clinical trial NCT06577090?

This trial is sponsored by Skye Bioscience, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06577090 being conducted?

This trial has 16 study locations across Alabama, California, Connecticut, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Obesity

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Obesity

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Related

Compare this shortlist side-by-side

Read our methodology - how this data is sourced, computed, and verified.
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.